The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
COSTEM 2021 | The potential of CAR-T in CLL
Robin Foà, MD, Sapienza University of Rome, Rome, Italy, talks on the potential use of chimeric antigen receptor T-cell therapy (CAR-T) to treat patients with chronic lymphocytic leukemia (CLL). Prof. Foà describes how patients with unfavourable genetic profiles are generally offered allogeneic hematopoietic stem cell transplantation (allo-HSCT) and that CAR-T therapy may be an alternative option for a subset of patients with poor prognostic genetic markers including 17p deletion and p53 mutation who relapse after first-line treatment. This interview took place at the 6th Congress on Controversies in Stem Cell Transplantation and Cellular Therapies (COSTEM), which took place virtually.
